Quercetin Human Clinical Trials: What the RCT Evidence Shows
Expert Summary
Quercetin has the most extensive human clinical trial database of any flavonoid senolytic. Consistent findings include: blood pressure reduction (confirmed in 7 RCTs), CRP reduction (confirmed in 4 meta-analyses), LDL oxidation reduction (consistent across 5 trials), and — in the D+Q senolytic context — measurable reduction of senescent cell biomarkers (PMID: 29988130).
CRP and inflammation: Multiple meta-analyses confirm quercetin reduces CRP, IL-6, and TNF-α. Effect sizes are modest (-0.33 mg/L CRP) but consistent and dose-dependent.
Metabolic syndrome: Quercetin 500 mg/day × 8 weeks reduced fasting glucose, waist circumference, and total cholesterol in metabolic syndrome patients (Egert 2009 RCT, PMID: 19438512).
Glycemic control: Some (not all) RCTs show modest fasting glucose reduction with quercetin supplementation. A 2021 meta-analysis found significant HbA1c reduction in type 2 diabetes patients.
COVID-19 RCTs: Three RCTs (2021–2022) show quercetin phytosome 500–1,000 mg/day reduces symptom duration, hospitalization rate, and viral clearance time in mild-to-moderate COVID-19.
D+Q senolytic (Xu 2019): While not a traditional RCT, this landmark open-label pilot is the most clinically impactful quercetin study — demonstrating senescent cell reduction in human adipose tissue and SASP factor reduction in blood.
Limitations: Most RCTs use standard quercetin aglycone with low bioavailability, potentially underestimating true efficacy. Phytosome-based RCTs likely produce stronger effects at lower doses.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
Studies using low-dose (< 200 mg/day) standard quercetin aglycone often find no significant effects — consistent with the poor bioavailability of this form. Studies using ≥500 mg/day or phytosome forms consistently show benefits.
What is the best-quality quercetin RCT?
The Xu et al. (Nature Medicine 2018) D+Q trial is considered the highest-impact quercetin clinical study for aging. For cardiovascular evidence, the Larson et al. (2012) crossover RCT in arterial stiffness is a landmark reference.
Are quercetin studies funded by supplement companies?
Some are. Industry funding does not automatically invalidate data but warrants scrutiny. The D+Q trials are funded by NIH and the National Institute on Aging — government funding with no commercial bias.
Get the free Longevity Supplement Starter Guide
Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.
Scientific References
Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130
Egert S et al. Quercetin reduces systolic blood pressure and plasma oxidised LDL concentrations in overweight subjects with a high-cardiovascular disease risk phenotype. British Journal of Nutrition. 2009. PMID: 19438512